dextera
Cardica hopes to raise $44M in public offering
Cardica unveiled the details of an upcoming public offering of stock, aimed at raising $43.9 million to support commercial efforts for the company’s MicroCutter XCHANGE 30 minimally invasive stapling system.
Cardica files for FDA clearance for MicroCutter device
Cardica shoots for Japanese approval
Losses widen in Cardica’s 4th quarter
Novadaq, KCI spike Luna wound imaging deal | Wall Street Beat
Novadaq Technologies (TSE:NDQ) said it and wound care giant Kinetic Concepts agreed to an amicable end to the co-development deal they inked in 2011 for the Luna wound imaging device.
Ocular Therapeutix eyes a $24M Series D extension | Wall Street Beat
Ocular Therapeutix said it closed a $23.8 million Series D extension round from existing backers for its sustained drug release technology to treat eye diseases.
The Bedford, Mass.-based medical device company said all of its current institutional investors ponied up for the round, including Polaris Ventures, Versant Ventures, SV Life Sciences, Sparta LLC, and Ascension Health Ventures.
Ocular Therapeutix is developing a punctum plug for the entry of the tear duct to release drug therapy to the surface of the eye over several months.
Report: Blackstone leads race for Allscripts | Wall Street Beat
Blackstone Group is said to be leading the bidding war for electronic medical records company Allscripts (NSDQ:MDRX) but the 2 sides are far from agreeing on a price, according to Reuters.
Citing 3 "people familiar with the matter," the news agency said a deal is "highly uncertain."
Policy analysts decry med-tech “Taxmageddon” | MassDevice.com On Call
MASSDEVICE ON CALL — Heritage Foundation senior policy analyst Curtis Dubay counts the 2.3% medical device tax among the worst "Taxmageddon" levies, measures prescribed through healthcare reform that the foundation dubbed "major job killers."
Counted alongside small business taxes and increased tax rates on capital gains and dividends, Dubay warned that the levy stands to hurt the industry.
Bruker tanks on Q2 earnings forecast | Wall Street Beat
Bruker Corp. (NSDQ:BRKR) shares took a double-digit dive this morning after the medical device company said it expects the European fiscal crisis to cut its 2ns-quarter per-share earnings roughly in half.
Bruker said it expects to report adjusted EPS of 11¢-13¢ for the 3 months ended June 30, on sales of about $420 million. Wall Street analysts were expecting adjusted EPS of 21¢.
Thoratec kills it in Q1, Wall Street shrugs | Earnings Roundup
Thoratec (NSDQ:THOR) started today up 7.2% as investors reacted to its stellar 1st-quarter numbers, but by the time the market closed THOR shares had fallen back to Earth to close at $34.46, down 0.1%.
The heart pump maker posted profits of $25.5 million, or 43¢ per diluted share, on sales of $126.8 million for the 3 months ended March 31.